Psychedelics
Reset Pharma Licenses Filament Drug to Combat Demoralization in Cancer Patients
Reset Pharma is specifically honing in on the plight of cancer patients.
The post Reset Pharma Licenses Filament Drug to Combat Demoralization in Cancer…
Filament Health (OTCQB: FLHLF) has inked a licensing deal with biotech firm Reset Pharmaceuticals Inc. to test a psychedelic-based drug for treating a severe form of emotional distress.
Under the agreement, Filament will license its botanical psilocybin drug candidate, PEX010, to Reset Pharma for a phase 2 clinical trial.
“Clinical trial data indicates that psilocybin may be effective in treating demoralization syndrome,” said Jan-Anders Karlsson, co-founder and interim CEO of Reset Pharma.
While there’s growing interest in psychedelics as potential treatments for various mental health conditions, Reset Pharma is specifically honing in on the plight of cancer patients who grapple with intense feelings of demoralization, risking suicide, and currently lacking effective treatments.
“We believe that demoralization syndrome is a complex and under-examined area of study,” Filament CEO Benjamin Lightburn said in a statement. “We are thrilled to develop a partnership with Reset Pharma and look forward to the advancement of our drug candidate in this important field.”
Multiple other entities have already licensed Filament’s PEX010 for clinical trials, looking to address issues such as opioid addiction and alcohol-related disorders.
The post Reset Pharma Licenses Filament Drug to Combat Demoralization in Cancer Patients appeared first on Green Market Report.
Psychedelic Search Trends in 2023
Take a look at this 2023 search volume chart. Do you think you can guess what’s happening? I was pretty shocked when I noticed this spike for December…
Here Are the Champions! Our Top Performing Stories in 2023
It has been quite a year – not just for the psychedelic industry, but also for humanity as a whole. Volatile might not be the most elegant word for it,…
Psilocybin shows promise for treating eating disorders, but more controlled research is needed
Recent psychedelic research shows promising results for mental illnesses and eating disorders, with surveys and reports indicating psilocybin-assisted…
